Featured Research

from universities, journals, and other organizations

Biomarkers Allow Doctors To Match Therapy To Patient

Date:
April 15, 2008
Source:
American Association for Cancer Research
Summary:
Genetic variations ensure that no two people are exactly alike, nor are their cancers. Researchers now have the tools and the knowledge to predict how individuals will respond to cancer therapy, enabling more precise and effective treatment.

Genetic variations ensure that no two people are exactly alike, nor are their cancers. Researchers now have the tools and the knowledge to predict how individuals will respond to cancer therapy, enabling more precise and effective treatment.

Researchers have identified two potential biomarkers that could help doctors monitor the effectiveness of treatment with sunitinib or bevacizumab for kidney and non-small cell lung cancer.

"Our work provides novel data on a potential biomarker for the monitoring of anti-angiogenic drug activity in cancer patients, as well as identifies a cell type that is a potential target for these agents," said Laura Vroling, M.Sc., a researcher in the Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.

The vascular endothelial growth factor (VEGF) receptor targeted agents bevacizumab and sunitinib have proven effective against several cancers, such as non-small cell lung cancer, colorectal and kidney cancer, but it is unclear which subset of patients will benefit most from these agents, researchers say. "Therefore, it is of great importance to identify and validate biomarkers for early response or duration of response," Vroling said.

Vroling and colleagues studied therapy-induced changes in a novel, rare, circulating cell population. They measured these candidate circulating endothelial progenitor cells (ccEPCs) characterized by the markers CD45neg, CD34bright and CD133neg during sunitinib or bevacizumab treatment.

They labeled them "candidate" cells because no data have proven definitively the phenotypic relationship between progenitor and blood-derived endothelial outgrowth cells, Vroling said.

Their study included 23 patients with renal cell cancer and 19 patients with non-small cell lung cancer. The researchers also monitored plasma levels of VEGF. They assessed tumor response with computed tomography scans according to the RECIST criteria.

"This is the first study to assess the kinetics of ccEPCs together with other circulating cells in the peripheral blood of patients with renal cell cancer during the first cycle of sunitinib treatment," Vroling said.

During a four-week "on" period of treatment with sunitinib, the ccEPC increases paralleled the rise in plasma VEGF levels; they decreased during the two-week "off" period, Vroling reports. Monocytes and hematopoietic progenitor cells (HPCs) demonstrated the opposite pattern, according to Vroling.

"In a preliminary analysis, we found a significant difference in the change of ccEPC numbers and VEGF levels after two weeks of treatment between patients with clinical benefit and progressive disease," Vroling said. "We also noted that an increase of ccEPCs was indicative of a longer progression-free survival in this small group of patients."

In the patients with non-small cell lung cancer treated with bevacizumab and erlotinib, ccEPC levels increased, while free plasma VEGF levels decreased. ccEPCs did not rise in a control group treated with erlotinib alone, Vroling said.

"These data suggest that ccEPCs are increased in cancer patients in an anti-angiogenic, treatment-specific way," she said. Furthermore, this effect does not seem to be related to plasma VEGF levels.

"In our study for the first time the behavior of two CD34bright cell populations, (CD45neg) candidate cEPCs and (CD45dim) HPCs were monitored and showed a different response of both cell populations during sunitinib or bevacizumab therapy. The role of ccEPCs in human tumor angiogenesis and their potential in prediction of treatment outcome of anti-VEGF therapy needs to be addressed in future, larger clinical cohorts," she said.

This research was presented at the American Association for Cancer Research 2008 Annual Meeting, April 12-16.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Biomarkers Allow Doctors To Match Therapy To Patient." ScienceDaily. ScienceDaily, 15 April 2008. <www.sciencedaily.com/releases/2008/04/080413161100.htm>.
American Association for Cancer Research. (2008, April 15). Biomarkers Allow Doctors To Match Therapy To Patient. ScienceDaily. Retrieved September 20, 2014 from www.sciencedaily.com/releases/2008/04/080413161100.htm
American Association for Cancer Research. "Biomarkers Allow Doctors To Match Therapy To Patient." ScienceDaily. www.sciencedaily.com/releases/2008/04/080413161100.htm (accessed September 20, 2014).

Share This



More Health & Medicine News

Saturday, September 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins